JP2007505836A - 麻疹サブユニットワクチン - Google Patents

麻疹サブユニットワクチン Download PDF

Info

Publication number
JP2007505836A
JP2007505836A JP2006526431A JP2006526431A JP2007505836A JP 2007505836 A JP2007505836 A JP 2007505836A JP 2006526431 A JP2006526431 A JP 2006526431A JP 2006526431 A JP2006526431 A JP 2006526431A JP 2007505836 A JP2007505836 A JP 2007505836A
Authority
JP
Japan
Prior art keywords
immunogenic composition
antigen
measles
proteosome
antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006526431A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007505836A5 (enExample
Inventor
デイビッド エス． バート，
ブライアン ジェイ． ワード，
ソフィー シャボー，
Original Assignee
アイディー バイオメディカル コーポレイション オブ ケベック
マクギル ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイディー バイオメディカル コーポレイション オブ ケベック, マクギル ユニバーシティ filed Critical アイディー バイオメディカル コーポレイション オブ ケベック
Publication of JP2007505836A publication Critical patent/JP2007505836A/ja
Publication of JP2007505836A5 publication Critical patent/JP2007505836A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2006526431A 2003-09-15 2004-09-15 麻疹サブユニットワクチン Withdrawn JP2007505836A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50311403P 2003-09-15 2003-09-15
PCT/US2004/030361 WO2005027964A1 (en) 2003-09-15 2004-09-15 Measles subunit vaccine

Publications (2)

Publication Number Publication Date
JP2007505836A true JP2007505836A (ja) 2007-03-15
JP2007505836A5 JP2007505836A5 (enExample) 2007-11-22

Family

ID=34375312

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006526431A Withdrawn JP2007505836A (ja) 2003-09-15 2004-09-15 麻疹サブユニットワクチン

Country Status (5)

Country Link
US (2) US20050152919A1 (enExample)
EP (1) EP1667713A1 (enExample)
JP (1) JP2007505836A (enExample)
CA (1) CA2538887A1 (enExample)
WO (1) WO2005027964A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015091795A (ja) * 2013-10-03 2015-05-14 日東電工株式会社 鼻粘膜ワクチン組成物
JP2015091792A (ja) * 2013-10-03 2015-05-14 日東電工株式会社 粘膜ワクチン組成物
JP2015091794A (ja) * 2013-10-03 2015-05-14 日東電工株式会社 注射ワクチン組成物
JP2015091793A (ja) * 2013-10-03 2015-05-14 日東電工株式会社 粘膜ワクチン組成物

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1372706B1 (en) * 2001-03-09 2010-12-01 ID Biomedical Corporation of Quebec Proteosome-liposaccharide vaccine adjuvant
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
JP4966661B2 (ja) * 2003-10-22 2012-07-04 アイディー バイオメディカル コーポレイション オブ ケベック 生得的免疫およびアレルギー性免疫を活性化させるための組成物および方法
NZ578727A (en) * 2004-06-25 2011-03-31 Brigham & Womens Hospital Proteosome compositions and methods for treating neurological disorders
WO2009132244A1 (en) * 2008-04-25 2009-10-29 Id Biomedical Corporation Of Quebec Methods for preparing immunogenic compositions
JP2010122205A (ja) * 2008-08-29 2010-06-03 Sysmex Corp 麻疹ウイルス検出方法、メンブレンアッセイ用試験具およびメンブレンアッセイ用試験キット
TW201618790A (zh) * 2014-10-02 2016-06-01 Nitto Denko Corp 經皮投與用疫苗醫藥組合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US5726292A (en) * 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
PT854729E (pt) * 1995-09-18 2004-08-31 Us Army Med Res Mat Com Usamrm Metodos melhorados para a producao de vacinas de subunidade multivalentes de proteossomas complexados nao covalentemente
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
NZ500779A (en) * 1997-05-20 2001-06-29 Galenica Pharmaceuticals Inc Triterpene saponin analogs having adjuvant and immunostimulatory activity
US6262029B1 (en) * 1998-08-14 2001-07-17 Galenica Pharmaceuticals, Inc. Chemically modified saponins and the use thereof as adjuvants
EP1031347B1 (en) * 1999-01-27 2002-04-17 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
GB9925966D0 (en) * 1999-11-02 1999-12-29 Petrik Juraj Threapeutic vaccines against variable viruses and other targets
DE19963124A1 (de) * 1999-12-24 2001-07-12 Roland Man Druckmasch Reinigungsmedium und dessen Verwendung
AUPQ520800A0 (en) * 2000-01-21 2000-02-17 Alfred Hospital Prime-boost vaccination strategy
JP3980884B2 (ja) * 2000-02-15 2007-09-26 アイディー バイオメディカル コーポレイション オブ ケベック プロテオソーム・インフルエンザ・ワクチン
JP2003528068A (ja) * 2000-03-17 2003-09-24 コリクサ コーポレイション 新規両親媒性アルデヒドならびにアジュバントおよび免疫エフェクターとしてのそれらの使用
EP1372706B1 (en) * 2001-03-09 2010-12-01 ID Biomedical Corporation of Quebec Proteosome-liposaccharide vaccine adjuvant

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015091795A (ja) * 2013-10-03 2015-05-14 日東電工株式会社 鼻粘膜ワクチン組成物
JP2015091792A (ja) * 2013-10-03 2015-05-14 日東電工株式会社 粘膜ワクチン組成物
JP2015091794A (ja) * 2013-10-03 2015-05-14 日東電工株式会社 注射ワクチン組成物
JP2015091793A (ja) * 2013-10-03 2015-05-14 日東電工株式会社 粘膜ワクチン組成物
US10071155B2 (en) 2013-10-03 2018-09-11 Nitto Denko Corporation Nasal mucosal vaccine composition

Also Published As

Publication number Publication date
US20090175903A1 (en) 2009-07-09
US20050152919A1 (en) 2005-07-14
CA2538887A1 (en) 2005-03-31
WO2005027964A1 (en) 2005-03-31
EP1667713A1 (en) 2006-06-14

Similar Documents

Publication Publication Date Title
US20090175903A1 (en) Measles subunit vaccine
JP4137640B2 (ja) 新規プロテオソーム−リポサッカリドワクチンアジュバント
ES2337901T3 (es) Vacuna de subunidad contra infeccion por el virus respiratorio sincicial.
US6743900B2 (en) Proteosome influenza vaccine
JP4021146B2 (ja) Ｒｓｖサブユニット成分およびインフルエンザウイルス調製物を含む多価免疫原性組成物
EP2066332A1 (en) Flu vaccine admixture of mannan and flu antigen
WO2005049076A1 (es) Polisacáridos capsulares de neisseria meningitidis como inmunopotenciadores mucosales y formulaciones resultantes
Berstad et al. Inactivated meningococci and pertussis bacteria are immunogenic and act as mucosal adjuvants for a nasal inactivated influenza virus vaccine
US20130315951A1 (en) Compositions and methods for stimulating an immune response against infectious agents
Glück Intranasal immunization against influenza
KR20090016659A (ko) 비로좀을 기제로 한 비강내 인플루엔자 백신
WO2008037033A1 (en) Flu vaccine admixture of mannan and flu antigen
TWI397419B (zh) 病毒顆粒的鼻內或吸入給藥
JP2020050605A (ja) 粘膜アジュバント
US20230149534A1 (en) Haptenized coronavirus spike proteins
WO2023060220A1 (en) Methods of immunization against coronavirus
EP1721618A2 (en) Proteosome influenza vaccine composition
HK1128077B (en) Intranasal influenza vaccine based on virosomes
HK1052629B (en) Proteosome influenza vaccine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070911

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070911

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080905

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20081023

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090915